Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19.
Zysman M, Asselineau J, Saut O, Frison E, Oranger M, Maurac A, Charriot J, Achkir R, Regueme S, Klein E, Bommart S, Bourdin A, Dournes G, Casteigt J, Blum A, Ferretti G, Degano B, Thiébaut R, Chabot F, Berger P, Laurent F, Benlala I. Zysman M, et al. Among authors: klein e. Eur Radiol. 2023 Dec;33(12):9262-9274. doi: 10.1007/s00330-023-09759-x. Epub 2023 Jul 5. Eur Radiol. 2023. PMID: 37405504 Free PMC article.
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Leroy H, Gadaud N, Bérard E, Klein E, Luquet I, Vial JP, Rieu JB, Lechevalier N, Tavitian S, Leguay T, Largeaud L, Bidet A, Delabesse E, Sarry A, de Grande AC, Récher C, Pigneux A, Bertoli S, Dumas PY. Leroy H, et al. Among authors: klein e. Cancer Med. 2024 Feb;13(3):e7003. doi: 10.1002/cam4.7003. Cancer Med. 2024. PMID: 38400682 Free PMC article.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Galtier J, Alric C, Bérard E, Leguay T, Tavitian S, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, de Grande AC, Sarry A, Pigneux A, Récher C, Bertoli S, Dumas PY. Galtier J, et al. Among authors: klein e. Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y. Blood Cancer J. 2021. PMID: 34775463 Free PMC article. No abstract available.
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
Dumas PY, Bertoli S, Bérard E, Largeaud L, Bidet A, Delabesse E, Leguay T, Leroy H, Gadaud N, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C. Dumas PY, et al. Among authors: klein e. Cancers (Basel). 2020 Jul 24;12(8):2044. doi: 10.3390/cancers12082044. Cancers (Basel). 2020. PMID: 32722211 Free PMC article.
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G, Faberes C, Bauduer F, Adiko D, Lifermann F, Dagada C, Lenoir C, Schmitt A, Klein E, Fort MP, Bijou F, Turcq B, Robbesyn F, Durrieu F, Versmée L, Madene S, Moldovan M, Katsahian S, Charles-Nelson A, Lascaux A, Mahon FX, Dulucq S. Etienne G, et al. Among authors: klein e. Cancer Med. 2021 Jun;10(11):3635-3645. doi: 10.1002/cam4.3921. Epub 2021 May 14. Cancer Med. 2021. PMID: 33988316 Free PMC article.
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A. Bertoli S, et al. Among authors: klein e. Cancers (Basel). 2020 Mar 25;12(4):773. doi: 10.3390/cancers12040773. Cancers (Basel). 2020. PMID: 32218221 Free PMC article.
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Gadaud N, Leroy H, Bérard E, Tavitian S, Leguay T, Dimicoli-Salazar S, Rieu JB, Luquet I, Largeaud L, Bidet A, Delabesse E, Klein E, Sarry A, de Grande AC, Bories P, Pigneux A, Récher C, Dumas PY, Bertoli S. Gadaud N, et al. Among authors: klein e. Leuk Lymphoma. 2022 Jun;63(6):1398-1406. doi: 10.1080/10428194.2021.2022140. Epub 2022 Jan 4. Leuk Lymphoma. 2022. PMID: 35634787
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome.
Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande AC, Despas F, Pigneux A, Récher C. Dumas PY, et al. Among authors: klein e. Blood Adv. 2020 Aug 25;4(16):3840-3849. doi: 10.1182/bloodadvances.2020002511. Blood Adv. 2020. PMID: 32790847 Free PMC article.
Erythropoietin levels in endocrinopathies.
Klein E, Brossaud J, Gatta B, Corcuff JB. Klein E, et al. J Endocrinol Invest. 2011 Jun;34(6):427-30. doi: 10.1007/BF03346707. Epub 2011 Apr 20. J Endocrinol Invest. 2011. PMID: 21508661
3,449 results